Test 3: AIDP Flashcards

1
Q

what neuro conditions have we learned thus far that are LMN or PNS

A

SCI below L2
vestibular hypofunctions
AIDP
CIDP
post-polio
polyneuropathies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

incidence of AIDP

A

100000 cases/year world wide

1-2 new cases per 100000 people

peak frequency of age is young adults or people in 5th to 8th decades

men more than women

white people

3-7% mortality rate

20% have lasting deficits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

etiology of AIDP

A

common post campylobacter jejuni bacterial infection (most common cause for subtypes that involve axonal damage)

common after influenza, epstein barr, cytomegalovirus

also common after vaccines and sx

90% of pts who got GBS had viral or bacterial infection in the 30 days prior

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

pathophysiology of AIDP

A

peripheral nerves

can attack sensory and motor

AIDP = min sensory

anti-inflammaotry process involving T cells and macrophages resulting in demyelination

particularly affects nodes of ranvier

can have damage all the way to axons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

S&S of AIDP

A

B ascending weakness

rapid and progressive initially

absence of DTRs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

AMAN: acute motor axonal neuropathy

A

more severe

more likely to have respiratory involvement and vent dependence

significant residual S&S

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

ASAN: acute sensory ascending neuropathy

A

sensory changes more prominent than weakness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

AMSAN: acute motor and sensory axonal neuropathy

A

ANS dysfunction is worse

may have:
- postural hypotension
- impaired sweating
- B&B changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

CIDP: chronic inflammatory demyelinating polyneuropathy

A

slower onset

may have relapses and remissions or progressive course over a year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

describe the progressive phase of AIDP

A

ascending demyelination that progresses anywhere from 2-6 weeks

4 weeks avg impairment

can ascend to cranial nn and cause facial weakness

can involve resp. mm (30% need vent)

50% progressive phase ends at 2 weeks; 90% at 4 weeks

can also attack ANS

usually in acute care to be ready in case they need mechanical vent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

plateau phase of AIDP

A

around 4 weeks when progression stops but remyelination has not fully occured

usually lasts 2-4 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

recovery phase of AIDP

A

nn start remyelinating and repairing

process takes months to years depending on level of damage

recovery happens proximal to distal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

clinical diagnostic features of AIDP

A

B weakness and falccidity

decreased/absent DTRs

absence of alternative dx

additional features:
- mild sensory
- progress after 2-4 weeks
- CN involvement
- autonomic dysfunction
- absence of fever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

CSF findings with AIDP

A

increased proteins after 1 week; increase continually with retest

less than 10 leukocytes/mm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

nn conduction velocity testing findings with AIDP

A

slowest at 2 weeks

decreased across entire nn

fibrillation potential present in case of axonal damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

acute phase medical management for AIDP

A

admit them
monitor changes
be prepared to intubate if needed

17
Q

2 main treatments of AIDP

A

high dose IVIG
plasmapheresis
dont have to do both

18
Q

describe IVIG treatment

A

IG treatment

protein attacks foreign mechanism

need high dose

5 day course via IV

best for non-ambulatory adults in 1st 2 weeks of onset

19
Q

describe plasmapheresis treatment

A

plasma exchange
filter blood plasma and remove antibodies
most effective w/i 2 weeks onset

20
Q

pleateau phase med management

A

wean off vent
get into therapies

21
Q

recovery phase medical management

A

track nn conduction recovery over time

refer to PT

22
Q

indicators of a worse prognosis

A

age >40
delay in diagnosis
delay in treatment
C-jejuni infection cause
if vented at any point

23
Q

better prognosis indicators

A

younger

no diarrhea preceding dx

lower level of disability S&S and admission

longer interval between onset and admission

no need for mechanical vent

24
Q

recovery with AIDP

A

most recover in 1st year

still see changes up to 3 years

about 20% do not reach full recovery (may have residual neuropathic pain, autonomic changes, and distal weakness)

25
Q

PT exam during early/progressive stage

A

likely in acute care or ICU specifically

ROM

Integ
-pressure injuries

Neuro
-DTRs
-sensation)

Cardio/Pulm
- ABGs: PO2 can’t be less than 70 mmHg
- pulse ox
- vital capacity less than 800mls

26
Q

PT intervention in early progressive stage

A

positioning
PROM
respiratory treatments
- clear secretions
- assisted cough
- spirometry

**high intensity exercise = WORSE functional status at this stage

27
Q

PT exam/eval for plateau phase

A

check all systems to see where they ended up

neuro = DTRs/sensory

MSK = ROM and mm function

skin = pressure injuries

cardio = vitals, respiratory health

28
Q

PT intervention at plateau phase

A

PROM; progress to AAROM and AROM

integ = edu and self management

cardiopulm = incentive spirometry, cough techniques, chest physiotherapy, breathing techniques

functional mobility treatments as able

29
Q

recovery phase PT exam and eval

A

neuro = DTRs and sensory

MSK = ROM and mm function

skin = pressure injuries

cardio = vitals and respiratory ability

30
Q

PT intervention for recovery phase

A

PROM; progress to AAROM and AROM

strength = eccentric not contraindicated but use judgement

integ = edu, self management, wound care

cardio = incentive spirometry, cough techniques, chest physiotherpay, breathing techniques, aerobic training (30-60 min 3x/wk at 70-90% HR max)

functional mobility = make salient and applicable

31
Q

DC planning depends on

A

severity/disability
how long each phase lasts
insurance coverage
functional mobility
psychosocial/environmental factors

32
Q
A